High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies

Joshua Kesterson, Kunle Odunsi, Shashikant Lele

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to determine the cardiac safety of pegylated liposomal doxorubicin (PLD) in patients receiving high cumulative doses of PLD. Materials and Methods: A retrospective chart review of women with gynecologic malignancies treated at Roswell Park Cancer Institute from 2002 through 2007 who received cumulative doses of PLD ≥400 mg/m2 was performed. Results: Forty-two of 116 patients met the inclusion criteria. The mean age at initiation of PLD therapy was 63 years. The mean cumulative dose of PLD was 663.9 mg/m2 (range 400-1,524 mg/m2). The mean cumulative number of cycles of PLD given was 9.8 (range 5-25). Multigated acquisition (MUGA) scans were obtained in 93% (39/42) of patients prior to or immediately following their first dose of PLD. The mean baseline ejection fraction was 63% (range 49-76%). Follow-up MUGA scans were performed on 7 patients (17%). Two of these patients had a decrease in their ejection fraction, but of only 3 and 1%. The remaining 5 patients who had follow-up MUGA scans had an average increase in their left ventricular ejection fraction of 4% (range 1-9%). No patients developed clinical evidence of congestive heart failure while being treated with PLD. There were no treatment interruptions or discontinuations due to cardiac toxicity. Conclusion: Cumulative doses of PLD ≥400 mg/m2 are not associated with clinically evident cardiac toxicity in gynecologic oncology patients.

Original languageEnglish (US)
Pages (from-to)108-111
Number of pages4
JournalChemotherapy
Volume56
Issue number2
DOIs
StatePublished - May 1 2010

Fingerprint

Neoplasms
liposomal doxorubicin
Cardiotoxicity
Stroke Volume
Heart Failure
Safety
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

@article{ed6f3da42c494c2b8302c18d493f1c31,
title = "High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies",
abstract = "Purpose: The purpose of this study was to determine the cardiac safety of pegylated liposomal doxorubicin (PLD) in patients receiving high cumulative doses of PLD. Materials and Methods: A retrospective chart review of women with gynecologic malignancies treated at Roswell Park Cancer Institute from 2002 through 2007 who received cumulative doses of PLD ≥400 mg/m2 was performed. Results: Forty-two of 116 patients met the inclusion criteria. The mean age at initiation of PLD therapy was 63 years. The mean cumulative dose of PLD was 663.9 mg/m2 (range 400-1,524 mg/m2). The mean cumulative number of cycles of PLD given was 9.8 (range 5-25). Multigated acquisition (MUGA) scans were obtained in 93{\%} (39/42) of patients prior to or immediately following their first dose of PLD. The mean baseline ejection fraction was 63{\%} (range 49-76{\%}). Follow-up MUGA scans were performed on 7 patients (17{\%}). Two of these patients had a decrease in their ejection fraction, but of only 3 and 1{\%}. The remaining 5 patients who had follow-up MUGA scans had an average increase in their left ventricular ejection fraction of 4{\%} (range 1-9{\%}). No patients developed clinical evidence of congestive heart failure while being treated with PLD. There were no treatment interruptions or discontinuations due to cardiac toxicity. Conclusion: Cumulative doses of PLD ≥400 mg/m2 are not associated with clinically evident cardiac toxicity in gynecologic oncology patients.",
author = "Joshua Kesterson and Kunle Odunsi and Shashikant Lele",
year = "2010",
month = "5",
day = "1",
doi = "10.1159/000312644",
language = "English (US)",
volume = "56",
pages = "108--111",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "2",

}

High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies. / Kesterson, Joshua; Odunsi, Kunle; Lele, Shashikant.

In: Chemotherapy, Vol. 56, No. 2, 01.05.2010, p. 108-111.

Research output: Contribution to journalArticle

TY - JOUR

T1 - High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies

AU - Kesterson, Joshua

AU - Odunsi, Kunle

AU - Lele, Shashikant

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Purpose: The purpose of this study was to determine the cardiac safety of pegylated liposomal doxorubicin (PLD) in patients receiving high cumulative doses of PLD. Materials and Methods: A retrospective chart review of women with gynecologic malignancies treated at Roswell Park Cancer Institute from 2002 through 2007 who received cumulative doses of PLD ≥400 mg/m2 was performed. Results: Forty-two of 116 patients met the inclusion criteria. The mean age at initiation of PLD therapy was 63 years. The mean cumulative dose of PLD was 663.9 mg/m2 (range 400-1,524 mg/m2). The mean cumulative number of cycles of PLD given was 9.8 (range 5-25). Multigated acquisition (MUGA) scans were obtained in 93% (39/42) of patients prior to or immediately following their first dose of PLD. The mean baseline ejection fraction was 63% (range 49-76%). Follow-up MUGA scans were performed on 7 patients (17%). Two of these patients had a decrease in their ejection fraction, but of only 3 and 1%. The remaining 5 patients who had follow-up MUGA scans had an average increase in their left ventricular ejection fraction of 4% (range 1-9%). No patients developed clinical evidence of congestive heart failure while being treated with PLD. There were no treatment interruptions or discontinuations due to cardiac toxicity. Conclusion: Cumulative doses of PLD ≥400 mg/m2 are not associated with clinically evident cardiac toxicity in gynecologic oncology patients.

AB - Purpose: The purpose of this study was to determine the cardiac safety of pegylated liposomal doxorubicin (PLD) in patients receiving high cumulative doses of PLD. Materials and Methods: A retrospective chart review of women with gynecologic malignancies treated at Roswell Park Cancer Institute from 2002 through 2007 who received cumulative doses of PLD ≥400 mg/m2 was performed. Results: Forty-two of 116 patients met the inclusion criteria. The mean age at initiation of PLD therapy was 63 years. The mean cumulative dose of PLD was 663.9 mg/m2 (range 400-1,524 mg/m2). The mean cumulative number of cycles of PLD given was 9.8 (range 5-25). Multigated acquisition (MUGA) scans were obtained in 93% (39/42) of patients prior to or immediately following their first dose of PLD. The mean baseline ejection fraction was 63% (range 49-76%). Follow-up MUGA scans were performed on 7 patients (17%). Two of these patients had a decrease in their ejection fraction, but of only 3 and 1%. The remaining 5 patients who had follow-up MUGA scans had an average increase in their left ventricular ejection fraction of 4% (range 1-9%). No patients developed clinical evidence of congestive heart failure while being treated with PLD. There were no treatment interruptions or discontinuations due to cardiac toxicity. Conclusion: Cumulative doses of PLD ≥400 mg/m2 are not associated with clinically evident cardiac toxicity in gynecologic oncology patients.

UR - http://www.scopus.com/inward/record.url?scp=77952263778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952263778&partnerID=8YFLogxK

U2 - 10.1159/000312644

DO - 10.1159/000312644

M3 - Article

VL - 56

SP - 108

EP - 111

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 2

ER -